"BTC OG Whale" BTC short position has an unrealized loss of over $900,000, while its associated address still holds long positions.
BlockBeats News, on October 20, according to HyperInsight monitoring, at 3:00 a.m. today (UTC+8), an address labeled as "BTC OG Whale" (0xb31) opened a 10x short position of 700 BTC at an average price of $109,100, which is now at an unrealized loss of over $900,000, with a total position of approximately $77.27 million.
It is worth noting that about 10 hours ago (UTC+8), this address deposited $30 million into HyperLiquid and opened a BTC long position. However, another address previously associated with it (0xc2a) still holds a 15x BTC and 5x ETH long position, with an unrealized profit of $3.66 million and a total position of approximately $260 million.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
A key leap toward the internationalization of the Korean won: The Bank of Korea launches a trial run of its 24/7 international settlement system, with full deployment set for January next year.
The Bank of Korea officially launched the trial operation of the "BOK Won International Payment Network" on Monday local time.
Offshore oil and gas module equipment company VME (VME.US) aiming for Nasdaq listing, plans to raise up to 30 million USD
Offshore oil and gas process module and separation equipment company VME Companies has applied for an IPO on Nasdaq, aiming to raise up to $30 million, with Kingswood as the sole bookrunner.
Hypertension drug developer Retension (RTSN.US) applies for US listing, plans to raise $58 million.
U.S. hypertension drug developer Retension Pharmaceuticals filed documents with the SEC last Friday, planning to raise up to $58 million through an initial public offering (IPO).
Pfizer (PFE.US) overseas price increase gains to be shared with the U.S. government: "Most Favored Nation" contract revealed, over twenty transactions still confidential
According to reports, under a new contract with the U.S. Department of Health and Human Services, Pfizer will share higher overseas drug revenues with the United States.
